Dublin, Feb. 02, 2017 -- Research and Markets has announced the addition of the "Subcutaneous Self-Administration Markets to 2024" report to their offering.
Because of the ongoing need for repeat dosing posed by chronic diseases, these indications represent significant drug volume and revenue opportunities, while simultaneously challenging the industry to develop products that meet the unique needs of the non-professional caregiver.
For drugs designed to be administered by the patient, therapy-specific packaging is improving adherence and treatment outcomes. In the area of delivery, reusable injection devices designed to accept prefilled syringes or drug cartridges are improving ease-of-use and increasing the alternative device share of the growing self-injection market. This report examines in detail the drugs, devices, therapeutics and markets that are set to drive the market for subcutaneous self-administration into the next decade.
Subcutaneous Self-Administration Markets to 2024 - What You Will Learn
- Provides detailed analysis of self-administered subcutaneous drug products, drug delivery and device strategies, and product development factors
- Assesses key markets, market dynamics and market demographics
- Analyzes therapeutic demand drivers and evaluates SC drug products in nine key therapeutic segments
- Provides market data and forecasts to 2024
- Profiles market sector participants, their product development activities, business strategies, and corporate alliances and affiliations
- Assesses the importance of alliances and partnerships on self-administered subcutaneous drug product commercialization
- Evaluates the impact of economic, technology, and regulatory factors
Key Topics Covered:
1. Executive Summary
2. Subcutaneous Self-Administration - Why it's Growing
- The Evolving Drug Pipeline
- Device and Packaging Technology Advances
- Shifting Patient Demographics
- Healthcare Economics
- Demand Drivers
- Innovation in Prefilled Device Designs
- Therapeutic Targets and Treatment
- Competitive Landscape
- Risk Factors
3. Subcutaneous Delivery Device Design Factors
- Ergonomics and Ease of Use
- Safety Features
- Needle Insertion Depth
- Dose Inspection/Injection Confirmation
- Lyophilized Drugs/Reconstitution
- High Viscosity Drugs
- High Volume Drugs
4. Subcutaneously Delivered Drugs - Delivery Device Strategies
- Handheld Devices
- Autoinjectors
- Pen Injectors
- Prefilled Syringes
- Other Handheld Devices
- Wearable Devices
- Patch Pumps
- Large Volume Wearable Devices
5. Subcutaneous Self-Administration
- Therapeutic Sector Product Analysis & Forecasts
- Anticoagulants
- Antivirals
- Autoimmune Diseases
- Diabetes
- Hematopoietics
- Hormone Replacement
- Neurology
- Osteoporosis
- Reproductive Health
6. Market Factors
- Regulatory Issues
- DTC Marketing
- Patient Education
7. Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/bn5bk2/subcutaneous
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Drug Delivery


TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Instagram Outage Disrupts Thousands of U.S. Users
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Washington Post Publisher Will Lewis Steps Down After Layoffs
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 



